Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunshine Biopharma has signed a Cross Referencing Agreement with a major pharmaceutical company for Anastrozole, a prescription generic drug for treatment of Breast Cancer.
Subscribe to our email newsletter
Sunshine will market and sell this new pharmaceutical product under its own label.
Sunshine is currently in the process of securing a Drug Identification Number ("DIN") for its own label of Anastrozole from Health Canada. The Company is also working on obtaining a Drug Establishment License ("DEL") from Health Canada.
Upon receipt of the DIN, Sunshine will be able to accept orders for its SBI-Anastrozole. Sunshine expects to build a portfolio of "SBI" label Generic Pharmaceuticals over time.
Revenues from the sales of Generic Products are intended to be used to finance the Company’s proprietary drug development program including Adva-27a, the Company’s flagship anticancer compound.
A Topoisomerase II inhibitor, Adva-27a is a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Breast Cancer cells, Pancreatic Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).
Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935.